A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its ...

Screening for both active and dormant tuberculosis (TB) infections simultaneously could enhance detection and improve ...

Tuberculosis (TB) killed approximately 1.25 million people globally in 2023, surpassing all other infectious diseases, ...

The 25% reduction in the price of pretomanid could save Global Drug Facility clients upwards of $3 million a year.

and WHO Europe (25 of 53 countries) to model and predict prison populations and TB infections among 4.9 million inmates from ...

and should be further tested in efficacy trials in TB endemic countries. Professor Helen McShane, Professor of Vaccinology at Oxford's Jenner Institute, explains: 'The only vaccine we currently have ...

“Countries [in Europe] have robust tuberculosis ... The post-pandemic comeback of social interactions and increased travel to TB-endemic regions have likely contributed to the spread.

and should be further tested in efficacy trials in TB endemic countries. This is the first time an aerosol BCG-challenge model will be used to test a new TB vaccine, and will be important in ...

The success of these trials could pave the way for more effective vaccines and bring hope to millions in TB-endemic countries across the globe.

The main strength of this phase two trial was the inclusion only of people living with HIV in South Africa, a TB-endemic country. The data from the phase two trial contributed to the decision to ...